Cargando…

Global incidence and prevalence of idiopathic pulmonary fibrosis

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive debilitating lung disease with considerable morbidity. Heterogeneity in epidemiologic studies means the full impact of the disease is unclear. METHODS: A targeted literature search for population-based, observational studies reporting...

Descripción completa

Detalles Bibliográficos
Autores principales:	Maher, Toby M., Bendstrup, Elisabeth, Dron, Louis, Langley, Jonathan, Smith, Gerald, Khalid, Javaria Mona, Patel, Haridarshan, Kreuter, Michael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8261998/ https://www.ncbi.nlm.nih.gov/pubmed/34233665 http://dx.doi.org/10.1186/s12931-021-01791-z

Ejemplares similares

Treatment of Acute Exacerbation of Idiopathic Pulmonary Fibrosis. A Call to Arms
por: Kreuter, Michael, et al.
Publicado: (2020)

Incidence, Prevalence, and Survival of Patients with Idiopathic Pulmonary Fibrosis in the UK
por: Strongman, Helen, et al.
Publicado: (2018)

Weight loss and outcomes in subjects with progressive pulmonary fibrosis: data from the INBUILD trial
por: Kreuter, Michael, et al.
Publicado: (2023)

Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
por: Costabel, Ulrich, et al.
Publicado: (2014)

Erratum to: Pirfenidone in Idiopathic Pulmonary Fibrosis: Expert Panel Discussion on the Management of Drug-Related Adverse Events
por: Costabel, Ulrich, et al.
Publicado: (2014)

Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives
por: Kreuter, Michael, et al.
Publicado: (2015)

The treatment of idiopathic pulmonary fibrosis
por: Woodcock, Hannah V., et al.
Publicado: (2014)

Economic consequences of idiopathic pulmonary fibrosis in Denmark
por: Hilberg, Ole, et al.
Publicado: (2018)

Eosinophil alveolitis in two patients with idiopathic pulmonary fibrosis
por: Brix, Ninna, et al.
Publicado: (2016)

Prevalence of anal fistula in the United Kingdom
por: Hokkanen, Suvi RK, et al.
Publicado: (2019)

Changes in management of idiopathic pulmonary fibrosis: impact on disease severity and mortality
por: Hyldgaard, Charlotte, et al.
Publicado: (2020)

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2017)

Recent advances in understanding idiopathic pulmonary fibrosis
por: Daccord, Cécile, et al.
Publicado: (2016)

Small Airways in Idiopathic Pulmonary Fibrosis: Quiet but Not Forgotten
por: Maher, Toby M.
Publicado: (2021)

Pirfenidone Treatment in Individuals with Idiopathic Pulmonary Fibrosis: Impact of Timing of Treatment Initiation
por: Maher, Toby M., et al.
Publicado: (2019)

Risk factors for diagnostic delay in idiopathic pulmonary fibrosis
por: Hoyer, Nils, et al.
Publicado: (2019)

PD-L1 Expression in Patients with Idiopathic Pulmonary Fibrosis
por: Kronborg-White, Sissel, et al.
Publicado: (2021)

Familial idiopathic pulmonary fibrosis in a young female
por: Sritharan, Sajitha S., et al.
Publicado: (2018)

Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results
por: Salih, Goran Nadir, et al.
Publicado: (2016)

Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis
por: Kreuter, Michael, et al.
Publicado: (2021)

Current and novel drug therapies for idiopathic pulmonary fibrosis
por: Adamali, Huzaifa I, et al.
Publicado: (2012)

Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat
por: Maher, Toby M., et al.
Publicado: (2019)

Targeting Human Herpesviruses: An Effective Strategy for Treating Idiopathic Pulmonary Fibrosis?
por: Maher, Toby M.
Publicado: (2021)

The number needed to treat and relevant between-trial comparisons of competing interventions
por: Jansen, Jeroen P, et al.
Publicado: (2018)

Fatigue in idiopathic pulmonary fibrosis measured by the Fatigue Assessment Scale during antifibrotic treatment
por: Kølner-Augustson, Line, et al.
Publicado: (2020)

Long-term clinical and real-world experience with pirfenidone in the treatment of idiopathic pulmonary fibrosis
por: Cottin, Vincent, et al.
Publicado: (2015)

Biomarkers for Interstitial Lung Abnormalities: A Stepping-stone Toward Idiopathic Pulmonary Fibrosis Prevention?
por: Maher, Toby M.
Publicado: (2022)

Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use
por: Diamantopoulos, Alex, et al.
Publicado: (2018)

Validation of the King’s Brief Interstitial Lung Disease questionnaire in Idiopathic Pulmonary Fibrosis
por: Prior, Thomas Skovhus, et al.
Publicado: (2019)

Management of idiopathic pulmonary fibrosis: selected case reports
por: Kreuter, Michael, et al.
Publicado: (2014)

Tele-Rehabilitation Program in Idiopathic Pulmonary Fibrosis—A Single-Center Randomized Trial
por: Cerdán-de-las-Heras, Jose, et al.
Publicado: (2021)

Reducing lung function decline in patients with idiopathic pulmonary fibrosis: potential of nintedanib
por: Woodcock, Hannah V, et al.
Publicado: (2013)

Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design
por: Santermans, Eva, et al.
Publicado: (2019)

Responsiveness and minimal clinically important difference of SGRQ-I and K-BILD in idiopathic pulmonary fibrosis
por: Prior, Thomas Skovhus, et al.
Publicado: (2020)

The therapy of idiopathic pulmonary fibrosis: what is next?
por: Somogyi, Vivien, et al.
Publicado: (2019)

The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review
por: Diamantopoulos, Alex, et al.
Publicado: (2018)

Organisation of diagnosis and treatment of idiopathic pulmonary fibrosis and other interstitial lung diseases in the Nordic countries
por: Bendstrup, Elisabeth, et al.
Publicado: (2015)

Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World
por: Polke, Markus, et al.
Publicado: (2021)

Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities
por: Glaspole, Ian, et al.
Publicado: (2021)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4nrk1ptesplkhupqtkoit8sefe